TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS)

TFG Asset Management GP Ltd acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 103,000 shares of the company's stock, valued at approximately $1,630,000. Keros Therapeutics accounts for about 0.3% of TFG Asset Management GP Ltd's investment portfolio, making the stock its 23rd biggest holding. TFG Asset Management GP Ltd owned approximately 0.25% of Keros Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares during the period. SG Americas Securities LLC bought a new position in Keros Therapeutics during the 4th quarter valued at approximately $388,000. Exchange Traded Concepts LLC purchased a new stake in Keros Therapeutics in the 4th quarter worth approximately $99,000. China Universal Asset Management Co. Ltd. lifted its holdings in Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after buying an additional 1,372 shares during the period. Finally, Handelsbanken Fonder AB grew its position in shares of Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after buying an additional 1,100 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Price Performance

NASDAQ:KROS traded down $0.62 during mid-day trading on Thursday, hitting $14.02. 550,423 shares of the company's stock were exchanged, compared to its average volume of 842,742. The company has a market cap of $569.42 million, a PE ratio of -2.69 and a beta of 1.32. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37. The business has a fifty day moving average price of $12.89 and a 200 day moving average price of $20.45.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. During the same period last year, the business earned ($1.21) earnings per share. On average, equities analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KROS. Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Tuesday, April 1st. Truist Financial dropped their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. HC Wainwright reduced their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Scotiabank lowered their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. Finally, Wells Fargo & Company cut their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $37.00.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.60% of the stock is owned by corporate insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.